Live and recent posts from across the Fediverse tagged #hybrozyme, aggregated by home.social.
Keytruda SC Using Alteogen’s Technology Wins Approval in Japan — BigGo Finance
Keytruda SC, Merck’s (MSD) immuno-oncology drug incorporating Alteogen’s (196170) subcutaneous (SC) formulation technology, has received manufacturing and marketing…
#EuropeSays #Japan #JP #ALT-B4 #Alteogen #berahyaluronidasealfa #Hybrozyme #Japan'sMinistryofHealth #KeytrudaSC #Kiject #LabourandWelfare #Merck(MSD) #Nihon #pembrolizumab
https://www.europesays.com/japan/93379/
https://www.europesays.com/ch/128687/ Alteogen Licenses ALT-B4 to Novartis in Deal Worth Up to $3.2 Billion, Reaffirming Value of SC Formulation Platform — BigGo Finance #ALTB4 #Alteogen #Biogen #GSK #Halozyme #Hybrozyme #Novartis #SamsungSecurities #SuhKeunHee
https://www.europesays.com/ch/125498/ This $3.2 Billion Novartis Bet Is Not a New Drug. It Is a Better Way to Take One #Hybrozyme #IT #Keytruda #Novartis #NVS
https://www.europesays.com/ch/125080/ Korea’s Alteogen inks $3.2 B deal with Novartis for development of Hybrozyme™-enabled subcutaneous products #Alteogen #BigPharma #Hybrozyme #Novartis #SOUTHKOREA
https://www.europesays.com/ch/124797/ Novartis taps Alteogen’s ALT-B4 for SC drug delivery in $3B deal #ALTB4 #AlteogenInc #AsiaPacific #BerahyaluronidaseAlfa #BioWorld #cancer #DealsAndM&A #DrugDelivery #Enhanze #Enzyme #Europe #HalozymeInc #Hybrozyme #Immune #Inflammatory #KeytrudaQlex #Merck&CoInc #Novartis #NovartisAG #SubcutaneousDrugDelivery #US
https://www.europesays.com/ch/124350/ Alteogen Signs $3.2 Billion Licensing Deal With Novartis #ALTB4 #Alteogen #Hybrozyme #KoreanBiotech #Novartis #SubcutaneousFormulation #TechnologyLicensing
https://www.europesays.com/ch/124270/ Alteogen Signs Up to $3.2 Billion Subcutaneous Injection Technology Export Deal with Novartis — BigGo Finance #ALTB4 #Alteogen #Biogen #Hybrozyme #JeonTaeYeon #Novartis #Tesaro
https://www.europesays.com/ch/124098/ Alteogen Licenses ALT-B4 Platform to Novartis in Deal Worth Up to $3.2 Billion #ALTB4 #Alteogen #Hybrozyme #Novartis #RecombinantHumanHyaluronidase #SubcutaneousFormulation #TechnologyLicensing